The role of autologous stem cell transplant (ASCT) in indolent lymphomas is a controversial issue. From 1994 to 1999, we performed ASCT with immunologically purged progenitor cells in 15 patients with advanced stage follicular lymphoma (FL) after early partial or complete remission. Results of the purging strategy and follow-up of minimal residual disease after transplant were analyzed with PCR amplification of bcl-2/IgH rearrangement for the t(14;18) translocation. A comparison of transplanted patients with a group of controls was carried out to evaluate differences in progression-free survival and overall survival. Eighty percent of patients received one chemotherapy regimen before ASCT and were in first remission. All the patients received cyclophosphamide plus hyperfractionated total body irradiation as the conditioning regimen. Nine patients were transplanted with bone marrow (BM) and six with peripheral blood progenitor cells (PBPC). Engraftment was delayed in one patient transplanted with BM. Two patients died during the transplant procedure. Ten of 12 evaluable patients were PCR positive in the BM for bcl-2 rearrangement at diagnosis. Six of them (60%) were still positive after chemotherapy, and one patient was transplanted with a positive hematopoietic product after purging. With a median follow-up of 27 months, six of eight evaluable patients still remain PCR negative in the BM. With a median follow-up of 4.7 years from diagnosis, progression-free survival was 83% (95% CI: 63-100). The risk of disease progression of non-transplanted patients was 19.2 times higher than that of transplanted patients (P = 0.01), but no differences were found in overall survival. Regarding patients in first remission, the risk of relapse was 12.6 times higher in non-transplanted than in transplanted patients (P = 0.04). This procedure seems to offer a good chance to achieve a PCR-negative 
Summary:
The role of autologous stem cell transplant (ASCT) in indolent lymphomas is a controversial issue. From 1994 to 1999, we performed ASCT with immunologically purged progenitor cells in 15 patients with advanced stage follicular lymphoma (FL) after early partial or complete remission. Results of the purging strategy and follow-up of minimal residual disease after transplant were analyzed with PCR amplification of bcl-2/IgH rearrangement for the t(14;18) translocation. A comparison of transplanted patients with a group of controls was carried out to evaluate differences in progression-free survival and overall survival. Eighty percent of patients received one chemotherapy regimen before ASCT and were in first remission. All the patients received cyclophosphamide plus hyperfractionated total body irradiation as the conditioning regimen. Nine patients were transplanted with bone marrow (BM) and six with peripheral blood progenitor cells (PBPC). Engraftment was delayed in one patient transplanted with BM. Two patients died during the transplant procedure. Ten of 12 evaluable patients were PCR positive in the BM for bcl-2 rearrangement at diagnosis. Six of them (60%) were still positive after chemotherapy, and one patient was transplanted with a positive hematopoietic product after purging. With a median follow-up of 27 months, six of eight evaluable patients still remain PCR negative in the BM. With a median follow-up of 4.7 years from diagnosis, progression-free survival was 83% (95% CI: 63-100). The risk of disease progression of non-transplanted patients was 19.2 times higher than that of transplanted patients (P = 0.01), but no differences were found in overall survival. Regarding patients in first remission, the risk of relapse was 12.6 times higher in non-transplanted than in transplanted patients (P = 0.04). This procedure seems to offer a good chance to achieve a PCR-negative 1 ). During the past few decades, clinical trials in FL have focused on comparisons of combinations of conventional drugs, including alkylating agents and anthracyclines, with no major impact on survival. 2, 3 Interferon-alpha showed an increment in progression-free survival in some studies, 4, 5 but without benefit in overall survival except in one study. 6 Recently, some new and promising agents have been studied. Fludarabine [7] [8] [9] [10] and chimeric anti CD20 antibody [11] [12] [13] have obtained very good responses, but results concerning their impact on survival and comparison with other treatments are still pending.
High-dose therapy has been shown to be a potentially curative modality for patients with relapsed diffuse aggressive non-Hodgkin lymphomas, 14 but its role in indolent lymphomas is controversial, since patients can survive for years with conventional therapy. Major questions have been the timing of the transplant 15 and tumor contamination of the stem cell product. 16 Considerable effort has been made to develop more sensitive techniques for the detection of minimal residual disease (MRD). The majority of patients with FL exhibit the t(14;18), with a reciprocal translocation of the bcl-2 and IgH loci (bcl-2/IgH), which can be detected by polymerase chain reaction (PCR), and can be used as a method of MRD detection. 17 In this paper, we present a prospective study of treatment with high-dose therapy followed by autologous stem-cell transplant (ASCT) with immunomagnetic purged progenitor cells in patients with early remission of FL. The efficacy of progenitor purging and MRD follow-up after transplant is analyzed by detection of bcl-2 rearrangement by PCR.
We also compare survival of these patients with a control group.
Patients and methods

Patients
Fifteen patients were enrolled in the study from June 1994 to November 1999. All patients were diagnosed with FL according to the REAL classification. The following criteria were required to undergo ASCT: to be younger than 60 years, have advanced disease at diagnosis (Ann Arbor III-IV), achieve partial or complete remission post chemotherapy and be able to receive total body irradiation. Partial remission was defined as less than 20% lymphocyte infiltration in bone marrow (BM), lymph nodes smaller than 3 cm, and absence of extra-nodal disease.
All the patients received cyclophosphamide (60 mg/kg i.v. daily for 2 consecutive days, total dose 120 mg/kg) plus hyperfractionated total body irradiation (total dose 12 Gy) as the conditioning regimen. G-CSF (at a dose of 5 g/kg/day) was used in all patients transplanted with BM, from day 1 post infusion until granulocyte recovery, and it was only used in the first patient transplanted with peripheral stem cells. Granulocyte recovery was defined as the first day of 3 consecutive days with more than 0.5 × 10 9 /l granulocytes and platelet recovery as the first day of 7 consecutive days with more than 20 × 10 9 /l platelets without transfusions.
Bone marrow (BM) and peripheral blood progenitor cells (PBPC) harvest and immunomagnetic purging
Autologous progenitor cells were obtained when patients were in partial or complete remission. From June 1994 to June 1996, stem cells were obtained from BM harvests. At least 2 × 10 8 /kg nucleated cells were required for purging and back-up. Subsequently, PBPC were used unless the initial cellularity was insufficient for purging. PBPC were collected using cyclophosphamide (i.v. 1.5 g/m 2 on day 1) and recombinant human G-CSF (s.c. at a daily dose of 5 g/kg/day) as mobilization regimen. Leukapheresis was initiated at a CD34 + cell count Ͼ2.5 × 10 6 /l and was performed daily until adequate numbers of CD34 + cells were collected for ex vivo purging (at least 4 × 10 6 /kg) and for back-up (2 × 10 6 /kg). The hematopoietic product was immunologically purged using a cocktail of monoclonal antibodies: CD19, CD20, CD22, CD23, CD37 (Baxter Europe, Unterschleissheim, Germany) and immunomagnetic beads coated with sheep antimouse immunoglobulins (Dynabeads M450, Dynal, Oslo, Norway), as previously described. 18 
Minimal residual disease follow-up
Results of the purging strategy and follow-up of MRD in BM after transplant were analyzed with PCR amplification of the bcl-2/IgH rearrangement for t(14;18) translocation in patients with FL.
DNA was isolated by classical techniques (proteinase-K digestion and phenol chloroform extraction). 19 PCR amplification was undertaken in the presence of 1 g of genomic DNA, 67 mm Tris-HCl (pH 8.8), 16.6 mm (NH 4 ) 2 SO 4 , 0.01% Tween-20, 2.5 mm MgCl 2 , 0.2 mm dNTPs, 25 pmol oligonucleotide primers specific for the major breakpoint region (MBR) of the bcl-2 gene (5′-CCTTTAGA-GAGTTGCTTTACGTG-3′) and the JH segments of the IgH gene (5′-ACCTGAGGAGACGGTGACC-3′) and 1 U Taq polymerase (DNA-Polymerase-C; Bio 101, La Jolla, CA, USA) in a total volume of 50 l. Amplification was performed for 35 cycles on a Hybaid (Teddington, UK) apparatus with the following protocol: 1 min at 94°C, 1 min at 65°C and 1 min at 72°C, increased to 10 min in the last cycle. To ensure that DNA could be amplified in all samples, a 172 bp fragment of the unrearranged bcl-2 gene was amplified using the 5′-GGAGGTCTGGCTTCATAC-3′ primer and the MBR primer specified above, under the same conditions. 10 l of PCR amplified products were separated on a 1.5% agarose gel, transferred to a nylon membrane (Hybond-N; Amersham, UK) and hybridized with an internal 32 P-bcl-2 probe (5′-GGCCTGTTTCAA-CACAGACCC-3′) labeled with T4 polynucleotide kinase (Pharmacia) according to the manufacturer's instructions. The sensitivity of the analysis was estimated by concurrent amplification of log dilutions of Karpas 422 cells (a bcl-2/IgH rearranged cell line obtained from the ATCC) in normal cells (buffy coat cells from healthy donors), and proved to be 10
.
Statistical analysis
Descriptive data are shown as median and range.
A comparison of transplanted patients with a group of controls was carried out to evaluate differences in progression-free survival (PFS) and overall survival (OS). PFS was defined as the time from diagnosis to the time of disease progression or last follow-up, and OS was defined as the time from diagnosis to death or date of last visit. We have been regularly keeping a prospective register of all cases of lymphomas diagnosed and treated at our institution since January 1992. All patients with lymphomas identified at our hospital are followed-up by a physician who fills out a computer-assisted protocol. For the purpose of the study, we re-assessed all the FL patients included in this register, and identified a group of 18 consecutive controls. The patients in the control group were diagnosed as FL at an advanced stage at diagnosis (Ann Arbor III-IV), were less than 60 years old, and had achieved complete or partial remission after chemotherapy (CHOP or C-MOPP). Patients in the control group did not undergo ASCT for different reasons: the diagnosis was made 1 or 2 years before the study began (two patients), the patient refused to enter the study (five patients) or the physician did not recommend the procedure (11 patients). The chi-square test was used to compare categorical variables, and Student's t-test was used to compare continuous variables. PFS and OS curves were constructed by the Kaplan-Meier method. Hazard ratios and 95% confidence limits were computed by Cox analysis, adjusting for potential confounding factors. All calculations were considered statistically significant at P Ͻ 0.05.
Results
Patient characteristics
Fifteen patients entered the study. The main characteristics of patients are shown in Table 1 . The median age was 43.9 years, all were diagnosed with FL in advanced stage with infiltration of the BM (87%) at diagnosis. The majority of the patients had only received one chemotherapy regimen before ASCT and were in first remission (80%).
All the patients were transplanted with immunomagnetic purged progenitors, nine with BM and six with PBPC. The mean number of nucleated cells collected in BM harvests was 2.9 × 10 3). PBPC could not be collected in one patient after mobilization because there were not enough CD34
+ cells for purging; this patient had FL in second remission. 
Toxicity of ASCT
Two patients (13%, 95% confidence interval, CI: 0-30%) died during the transplant. One died on day +23 post ASCT with BM, due to respiratory distress syndrome with a recovered granulocyte count since day +16 post ASCT. Microorganisms did not grow in blood cultures. The other patient died on day +17 post ASCT with peripheral progenitors, due to a lung hemorrhage without evidence of engraftment. All of the blood cultures were again negative. Engraftment was delayed in one patient (Ͼ6 months). After 2 years of follow-up, this patient developed a myelodysplastic syndrome. Currently, 5 years after the ASCT, she does not require growth factors or transfusion support.
Fourteen patients (94%) had fever during the transplant, and six of them (40%) developed a documented infection (three had bacteremia).
Data on hematological recovery are shown in Table 2 . Granulocyte recovery (27.7 vs 13 days, P = 0.02) and platelet recovery (36.6 vs 11.8, P = 0.01) was significantly faster in patients transplanted with peripheral blood progenitors cells than in patients transplanted with bone marrow.
Minimal residual disease
Results are shown in Figure 1 . In summary, 10 out of 12 evaluable patients (83%) were PCR positive for bcl-2 rearrangement in BM at diagnosis. Six of them (60%) were still positive after chemotherapy, and only one was transplanted with a PCR-positive hematopoietic product after purging (efficacy of the purging procedure was 83%). With a median follow-up of 27 months, six out of eight evaluable patients still remain PCR negative in BM. One patient relapsed clinically at 54 months post ASCT, but he is one of the two patients who had always been PCR negative, even after relapse.
Progression-free survival (PFS) and overall survival (OS): comparison with patients who were not transplanted
Comparisons between transplanted patients and non-transplanted patients are shown in Table 3 . The only difference between the two populations is that transplanted patients were younger, even though all control patients were younger than 60 years. For this reason, age was introduced as a covariate in the Cox analysis. 
Table 3
Comparison between transplanted and non-transplanted patients PFS and OS curves are shown in Figures 2 and 3 , respectively. With a median follow-up of 4.7 years (limits: 0.7-8) from diagnosis, PFS was 83% (95% CI: 63-100). The risk of disease progression in non-transplanted patients was 19.2 times higher than transplanted patients (95% CI: 2-195; P = 0.01), but there were no differences in OS (hazard ratio: HR 1.94; 95% CI 0.3-16; P = 0.47). The risk of disease progression in the 16 control patients not transplanted after first remission was 12.6 times higher than the risk of disease progression in the 12 patients transplanted in first remission (95% CI: 1-23.2; P = 0.047), but again, there were no differences in OS (HR 1.7; 95% CI 0.3-9.5; P = 0.5). 
Discussion
In our study, the use of immunomagnetic purging is an efficient method to render negative the PCR in hematopoietic progenitors of patients with FL in partial or complete remission. Recent studies have shown that negativity of a previously positive PCR in the infused progenitor cells is associated with a lower risk of relapse. 20, 21 Moreover, serial PCR analyses in the BM, to determine the molecular response after ASCT, correlated with durable remissions. [22] [23] [24] A positive PCR in all BM samples after transplant is associated with a high risk of relapse, a positive PCR in some samples is associated with an intermediate risk and when the PCR is always negative the risk of relapse is very low. 22 In patients in whom residual lymphoma cells were detected in the BM in the early post-transplant period, but subsequent samples contained no detectable lymphoma cells, as occurred in some of our patients, the risk of relapse is also very low. 22 In addition, patients who achieved molecular remissions after conventional chemotherapy also had better PFS. 25 Nowadays, and according to these results, the different treatments of patients with FL should be directed at attaining a PCR-negative state, and ASCT with immunomagnetic purged hematopoietic progenitors is a good therapeutic method to achieve this objective.
The reported median times to progression in conventionally treated patients diagnosed with FL after first complete remission range from 12 to 36 months, and the median survival is arround 7 to 10 years. 2, 3 In our study, the PFS curve of transplanted patients shows an advantage over a comparable group of patients treated with conventional therapy. The timing of the transplant in patients with FL has been a major question, because patients with FL can survive for years with conventional therapy. On the other hand, patients who have failed multiple regimens and have developed resistant disease are less likely to benefit from ASCT. 26, 27 Other groups have demonstrated better PFS in patients transplanted in second remission, 28 but in our study, although our group is small, this advantage is maintained even in patients transplanted in first remission. Nevertheless, we do not find differences in OS between transplanted and non-transplanted patients.
Caution about the possible benefit of ASCT is demanded by the toxicity of the treatment. The use of TBI in the conditioning regimen could have played a role in the high treatment-associated mortality of this group. Although FL is very sensitive to radiotherapy, 2,3 alternative regimens may be associated with lower mortality rates. The recent use of PBSC instead of BM has decreased the acute morbidity of the procedure. 29 Another concern is related to long-term morbidity. One of our patients had prolonged failure of RBC and platelet recovery, and finally developed myelodysplasia. Similar results have been reported by others. 30, 31 Therefore, despite the reservations, it does appear that ASCT with immunomagnetically purged progenitor cells in patients with advanced stage FL after early partial or complete remission (even in those in first remission) offers a good chance to achieve a PCR-negative state and prolonged freedom from recurrence for younger patients. Larger numbers of patients and longer follow-up are needed to evaluate Bone Marrow Transplantation the real impact of this procedure on OS. According to these results, prospective randomized trials are warranted.
